Discover investment opportunities in Best Stocks To Buy Under $13 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks To Buy Under $13 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks To Buy Under $13 using our Smart AI Filter.
8 stocks found for "Best Stocks To Buy Under $13"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.79 Risk measure | ±66.5% Price volatility | 4.1 Valuation | 0.00% Annual yield | |||
1.46 Risk measure | ±68.0% Price volatility | -1.9 Valuation | 0.00% Annual yield | |||
0.92 Risk measure | ±100.0% Price volatility | -64.6 Valuation | 0.00% Annual yield | |||
0.61 Risk measure | ±38.9% Price volatility | 6.7 Valuation | 5.08% Annual yield | |||
1.06 Risk measure | ±43.4% Price volatility | 5.8 Valuation | 3.42% Annual yield | |||
1.05 Risk measure | ±36.3% Price volatility | 8.2 Valuation | 9.82% Annual yield | |||
2.45 Risk measure | ±100.0% Price volatility | 2.3 Valuation | 0.00% Annual yield | |||
1.99 Risk measure | ±100.0% Price volatility | -76.3 Valuation | 14.14% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Summit Therapeutics Inc SMMT and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.
Read moreMerely a year ago, Coty Inc. stock (NYSE: COTY) was priced around $10, but it now hovers close to $4, having declined more than 50% from its peak. This significant drop is indicative of more than just market fluctuations—it highlights the pressures that are heavily impacting one of the largest beauty firms globally.
Read moreQ: What are the pros and cons of investing in Ford (F) under $13?
A: Ford offers potential value for investors due to its strategic shift towards electric vehicles. However, the automotive sector faces uncertainties like fluctuating raw material costs and economic downturns that can impact sales.
Q: Is American Airlines Group (AAL) a good buy for a value-focused investor?
A: AAL is attractive to value investors aiming for recovery post-pandemic, but airfare volatility and operational costs pose significant risks to its financial stability.
Q: How does Coty's (COTY) focus on beauty products impact its growth potential?
A: Coty shows growth potential with its focus on skincare and fragrance sectors. However, market share in the competitive beauty industry is a challenge that might affect its performance.
Q: What are the potential risks of investing in Nokia (NOK)?
A: Nokia faces strong competition in the technology sector, particularly in 5G infrastructure. Supply chain issues and market share loss to rivals are key risks.
Q: Is GoPro (GPRO) a viable option for long-term growth?
A: Some investors see GoPro as a growth play due to its innovative camera products. However, saturation in the camera market and competition from smartphones remain concerns.
Q: How might Summit Therapeutics (SMMT) appeal to biotech investors?
A: SMMT is of interest due to its focus on antibiotic innovation. However, biotech investments carry high risks due to regulatory hurdles and clinical trial outcomes.